Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Evaluation of Risk Factors Associated to Prescription of Benzodiazepines and its Patterns in a Cohort of Patients from Mental Health: A Real World Study in Spain
1
x
$
30.00
Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data
1
x
$
30.00
Charles B. Nemeroff, MD, PhD: The Role of GABA in the Pathophysiology and Treatment of Anxiety Disorders
1
x
$
30.00
Eric Vermetten, MD, PhD: Positron Tomographic Emission Study of Olfactory Induced Emotional Recall in Veterans with and without Combat-Related Posttraumatic Stress Disorder
1
x
$
30.00
Catatonia and CPK Elevation in Neurosyphilis
1
x
$
30.00
Psychopharmacology Bulletin VOL 49 No. 1, 2019 - Full Issue Stacked PDF
1
x
$
90.00
David V. Sheehan, MD, MBA: Current Approaches to the Pharmacologic Treatment of Anxiety Disorders
1
x
$
30.00
Escitalopram Induced SIADH in an Elderly Female: A Case Study
1
x
$
30.00
Epidural Analgesia in Ventral Hernia Repair: An Analysis of 30-day Outcomes
1
x
$
30.00
Probable Olanzapine-Related Idiopathic Intracranial Hypertension in an Adolescent with First-Episode Psychosis
1
x
$
30.00
Boadie W. Dunlop, MD: Disturbed Glucose Metabolism Among Patients Taking Olanzapine and Typical Antipsychotics
1
x
$
30.00
Fabiana da Silva Alves, MS: The Revised Dopamine Hypothesis of Schizophrenia: Evidence from Pharmacological MRI Studies with Atypical Antipsychotic Medication
1
x
$
30.00
Psychopharmacology Bulletin VOL 48 No. 2, 2018 - Full Issue Stacked PDF
1
x
$
90.00
View Cart
Checkout
Home
valbenazine
Sort by
Popularity
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
$
0.00
Add to cart
Details
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
$
0.00
Add to cart
Details
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
$
0.00
Add to cart
Details
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects
$
0.00
Add to cart
Details
Psychopharmacology Bulletin VOL 47 No. 3, 2017 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Page load link
Go to Top
